Business News

    Nova Eye Medical (ASX:EYE) FDA clears iTrack Advance for US launch

    Article Image

    The FDA has approved Nova Eye Medical's iTrack Advance device for canal-based glaucoma surgery in the US.

    The iTrack Advance is a high-precision handheld delivery system for injecting viscoelastic fluid into the eye's main drainage canal, aiming to treat glaucoma by clearing blockages that cause elevated eye pressure.

    The device appeals to glaucoma and cataract surgeons as well as comprehensive surgeons and can be used for standalone procedures or combined with cataract surgery.

    Nova Eye plans a full product launch at the American Society of Cataract and Refractive Surgery conference in San Diego on May 5-8, 2023.

     

    Disclaimer

    Grafa is not a financial advisor. You should seek independent, legal, financial, taxation or other advice that relates to your unique circumstances. Grafa is not liable for any loss caused, whether due to negligence or otherwise arising from the use of, or reliance on the information provided directly or indirectly by use of this platform.

    Publisher
    Grafa